Skip to main content
SpringerLink
Log in

Schedule‐dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Vinorelbine and paclitaxel are new anticancer agents that bind to distinct sites on tubulin and affect microtubules in opposite ways. Clinical studies of combinations of these agents have been in progress against breast cancer and some solid tumors. To clarify the optimal schedule for this combination, we studied the schedule‐dependent cytotoxic effects of vinorelbine and paclitaxel against the human lung carcinoma cell line A549, the breast carcinoma cell line MCF7, the ovarian carcinoma cell line PAl, and the colon carcinoma cell line WiDr in vitro. Tumor cells were incubated with vinorelbine and paclitaxel simultaneously for both 24 h and 5 days. Cells were also incubated with vinorelbine for 24 h, followed by a 24‐h exposure to paclitaxel and vice versa. Cell growth inhibition after 5 days was determined by MTT assay. The effects of drug combinations at the concentration producing 80% cell growth inhibition (IC80) were analyzed by the isobologram method (Steel and Peckham).

The simultaneous exposures to vinorelbine and paclitaxel for both 24 h and 5 days produced additive effects for all four cell lines. The sequential exposure to vinorelbine followed by paclitaxel produced additive effects for the PAl and WiDr cells, additive and antagonistic effects for the A549 cells, and antagonistic effects for the MCF7 cells. The sequential exposure to paclitaxel followed by vinorelbine produced additive effects for the A549, and PAl cells, additive and antagonistic effects for the MCF7 cells, and antagonistic effects for the WiDr cells.

Our findings suggest that the simultaneous but not the sequential administration of vinorelbine and paclitaxel may be optimal schedule for this combination of these two agents. Applications of this schedule dependency may be beneficial for the treatment of breast cancer and other solid tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bender RA, Hamel E, Hande KR: Plant alkaloids. In: Chabner BA, Collins JM (eds) Cancer Chemotherapy: principle and practice. Lippincott Philadelphia, 1992, pp 253–275

    Google Scholar 

  2. Mangeney P, Andriamialisoa RZ, Langlois N, Langlois Y, Potier PA: New class of antitumor compounds: 50-nor and 50,60-secoderivatives of vinblastine-type alkaloids. J Org Chem 44: 3765–3768, 1979

    Google Scholar 

  3. Maral R, Bourut C, Chenu E, Mathe G: Experimental in vivo cross-resistance of vinca alkaloid drugs. Cancer Chemother. Pharmacol 5: 197–199, 1981

    Google Scholar 

  4. Maral R, Bourut C, Chenu E, Mathe G: Experimental antitumor activity of 50-nor anhydrovinblastine navelbine. Cancer Lett 22: 49–54, 1984

    PubMed  Google Scholar 

  5. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A: Experimental antitumor activity of Navelbine. Semin Oncol 16 (suppl 4): 15–20, 1989

    PubMed  Google Scholar 

  6. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V: In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Sem Oncol 16 (suppl 4): 5–8, 1989

    Google Scholar 

  7. Besenval M, Delgado M, Demarez JP, Krikorian A: Safety and tolerance of navelbine in phase I-II clinical studies. Semin Oncol 16 (suppl 4): 37–40, 1989

    PubMed  Google Scholar 

  8. Depierre A, Lemarie E, Dadouis G, Gamier G, Jacoulet P, Dalphin JC: A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14: 115–119, 1991

    PubMed  Google Scholar 

  9. Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L: Phase-II study of navelbine in advances breast cancer. Semin Oncol 16 (suppl 4): 33–36, 1989

    PubMed  Google Scholar 

  10. George MJ, Heron JF, Kerbrat P, Chauvergne J, Goupil A, Lebrun D, Guastalla JP, Namer M, Bugat R, Ayme Y, Toussaint C, Lhomme C: Navelbine in advanced ovarian epitherial cancer: a study of the French Oncology Centers. Semin Oncol 16 (suppl 4): 30–32, 1989

    Google Scholar 

  11. Wani MC, Taylor HL, Wall ME, Coggen P, Mcphail AT: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and agents from Taxus brevifolia. Am Chem Soc 93: 2325–2327, 1971

    Google Scholar 

  12. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665–667, 1979

    PubMed  Google Scholar 

  13. Kumar N: Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435–10441, 1981

    PubMed  Google Scholar 

  14. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 50-triphosphate or microtubuleassociated proteins. Biochemistry 20: 3247–3252, 1981

    PubMed  Google Scholar 

  15. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JKV, Tormey DC, Swaminathan S, Trump DL: Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 71: 1179–1184, 1987

    PubMed  Google Scholar 

  16. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS: Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171–1177, 1987

    PubMed  Google Scholar 

  17. Wiernik PH, Schwartz EL, Eizig A, Straumann JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5: 1232–1239, 1987

    PubMed  Google Scholar 

  18. Donehower RC, Rowinsky EK: An overview of experience with taxol (paclitaxel) in the USA. Cancer Treat Rev 19 (suppl. C): 63–78, 1993

    PubMed  Google Scholar 

  19. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273–279, 1989

    PubMed  Google Scholar 

  20. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J NatI Cancer Inst 83: 1797–1805, 1991

    Google Scholar 

  21. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes E, Gross HM, Enrique D, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK: Phase II study of taxol in untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85: 384–388, 1993

    PubMed  Google Scholar 

  22. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC (628503), a taxol analogue. Cancer Res 51: 4845–4852, 1991

    PubMed  Google Scholar 

  23. Adams DJ: Synergy of navelbine-taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Can Res 35: 327, 1994 (abstract)

    Google Scholar 

  24. Gomi K, Ashizawa T, Asada M, Sugiyama K, Okabe M: Studies on KW2307 (navelbine). vii. Combination effects of KW-2307 with taxol against murine and human tumors in vitro and in vivo. Proc Jap Can Assoc 54: 619, 1995 (abstract)

    Google Scholar 

  25. Knick VC, Eberwein DJ, Miller CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J NatI Cancer Inst 19; 87: 1072–1077, 1995

    Google Scholar 

  26. Budman DR, Stiel CA, Kreis W: In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: sequence dependent effects causing synergism and antagonism. Proc Am Assoc Can Res 37: 365, 1996 (abstract)

    Google Scholar 

  27. Photiou A, Shah P, Leong LK, Moss J, Retsas S: In vitro synergy of paclitaxel and vinorelbine against human melanoma cell lines. Eur J Cancer 33: 463–470, 1997

    PubMed  Google Scholar 

  28. Culiner S, Roch I, Pinguet F: Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and doseescalation study in patients with anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 17: 135a, 1998 (abstract)

    Google Scholar 

  29. Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T: Combination of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer 75: 57–63, 1998

    PubMed  Google Scholar 

  30. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 22 (2 Suppl 5): 66–70,1995

    PubMed  Google Scholar 

  31. Chang AY, DeVore R, Johnson D: Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non90 Y Kano et al. small cell lung cancer. Semin Oncol 23 (2 Suppl 5): 19–21, 1996

    Google Scholar 

  32. Michelotti A, Gennari A, Salvadori B, Giannessi PG, Baldini E, Tibaldi C, Da Prato M, Conte PF: Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Semin Oncol 23 (5 Suppl 11): 38–40, 1996

    Google Scholar 

  33. Parimoo D, Jeffers S, Muggia FM: Severe neurotoxicity from vinorelbine-paclitaxel combinations J Natl Cancer Inst 88: 1079–1080, 1996

    PubMed  Google Scholar 

  34. Retsas S, Mohith A, Mackenzie H: Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs 7: 161–165, 1996

    PubMed  Google Scholar 

  35. Iaffaioli RV, Facchini G, Tortoriello A, Caponigro F, Illiano A, Gentile M, Gravina A, Muto P: Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemother Pharmacol 41: 86–90, 1997

    PubMed  Google Scholar 

  36. Romero Acuna L, Langhi M, Perez J, Leone B, Machiavelli M, Lacava J, Vallejo C, Romero A, Cuevas J, Ortiz E, Grasso S, Amato M, Salvadori M, Rodriguez R, Barbieri M, Romero Acuna J: Grupo Oncologico Cooperativo del Sur (GOCS). Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 16: 661, 1997 (abstract)

    Google Scholar 

  37. Vici P, Amodio A, Di Lauro L, Paolettei G, Foggi P, Squilloni E, Gionfra T, Conti F, Lopez M: Simultaneous infusion of vinorelbine and paclitaxel in advanced breast cancer. Am Soc Clin Oncol 16: 688, 1997 (abstract)

    Google Scholar 

  38. Cocconi G, Mambrini A, Vasini G, Quarta MC, Bella M, Gentile A, Di Sarra S: Vinorelbine combined with paclitaxel, administered in a continuous 96-hour iv infusion, in pretreated advanced breast cancer patients. Proc Am Soc Clin Oncol 17: 208a, 1998 (abstract)

    Google Scholar 

  39. Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingstone RB: Paclitaxel/vinorelbine chemotherapy with concurrent for metastatic breast cancer: phase I-II study in doxorubicintreated patients. Proc Am Soc Clin Oncol 17: 139a, 1998 (abstract)

    Google Scholar 

  40. Gardin G, Pronzato P, Tognoni A, Vigani A, Vaira F, Gasco M, D'Amico M, Vecchio S, Antonelli G, Banfi A, Queirolo P, Campora E, Sertoli MR: A phase II trial of vinorelbine and Paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline containing chemotherapy. Proc Am Soc Clin Oncol 17: 142a, 1998 (abstract)

    Google Scholar 

  41. Willey J, Ibrahim NK, Walters R, Rahman Z, Valero V, Esteva FJ, Hortobagyi GN: Vocal cord paralysis secondary to biweekly vinorelbine and paclitaxel by simultaneous 3-hour infusion with G-CSF support as a frontline therapy for metastatic breast cancer patients. Proc Am Soc Clin Oncol 17: 183a, 1998 (abstract)

    Google Scholar 

  42. Martin M, Casado A, Perez Segura P, Garcia Carbonero I, Diaz Rubio E: Paclitaxel plus vinorelbine in metastatic breast Cancer patients with contraindications to receive anthracyclines. Oncology Huntingt. 12 (1 Suppl 1): 28–30, 1998

    Google Scholar 

  43. Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, Citarella A, Carola M, Marzano N, Laffaioli RV: Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47: 91–97, 1998

    PubMed  Google Scholar 

  44. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85–91, 1979

    PubMed  Google Scholar 

  45. Kano Y, Sakamoto S, Kasahara T, Akutsu M, Inoue Y, Miura Y: In vitro effects of amsacrine in combination with other anticancer agents. Leukemia Res 15: 1059–1064, 1991

    Google Scholar 

  46. Rideout DC, Chou TC: Synergism, antagonism, and potentiation of chemotherapy. In: Chou TC and Rideout DC, (eds) Synergism and Antagonism in Chemotherapy. San Diego: Academic Press: 3–60, 1991

    Google Scholar 

  47. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93–141, 1988

    Google Scholar 

  48. Greco WR, Bravo G, Parsons JC: The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331–385, 1995

    PubMed  Google Scholar 

  49. Frey CM: Role of modelling in joint action studies. J Natl Cancer Inst 86: 1493–1495, 1994

    PubMed  Google Scholar 

  50. Kano Y, Ohnuma T, Okano T, Holland JF: Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 48: 351–356, 1988

    PubMed  Google Scholar 

  51. Kano Y, Suzuki K, Akutsu M, Suda k, lnoue Y, Yoshida M, Sakamoto S, Miura Y: Effects of CPT-11 in combination with other anticancer agents in culture. lnt J Cancer 50: 604–610, 1992

    Google Scholar 

  52. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Adachi K: In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 42: 91–98, 1998

    PubMed  Google Scholar 

  53. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F. Nicot G: Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42: 545–547, 1992

    PubMed  Google Scholar 

  54. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13: 180–190, 1995

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Medical Oncology Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

    Yasuhiko Kano, Miyuki Akutsu & Saburo Tsunoda

  2. Division of Laboratory Medicine, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

    Kenichi Suzuki

  3. Division of Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

    Jiro Ando

Authors
  1. Yasuhiko Kano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miyuki Akutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenichi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiro Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Saburo Tsunoda
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kano, Y., Akutsu, M., Suzuki, K. et al. Schedule‐dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res Treat 56, 79–90 (1999). https://doi.org/10.1023/A:1006254315174

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006254315174

Search

Navigation